Cargando…
An Update on Common Pharmaceuticals in the Prevention of Pancreatic Cancer
In this review, we aim to update readers about the most recent studies on common pharmaceuticals and their association with pancreatic cancer risk. The use of prophylactic aspirin, metformin, beta-blockers, and statins has been studied in the past but showed inconclusive results in the reduction of...
Autores principales: | Miyaki, Candace, Lynch, Launa M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246430/ https://www.ncbi.nlm.nih.gov/pubmed/35800820 http://dx.doi.org/10.7759/cureus.25496 |
Ejemplares similares
-
Magic of a Common Sugar Pill in Cancer: Can Metformin Raise Survival in Pancreatic Cancer Patients?
por: Gyawali, Mallika, et al.
Publicado: (2021) -
Diabetes Mellitus in the Middle-Aged and Elderly Population (>45 Years) and Its Association With Pancreatic Cancer: An Updated Review
por: Kaleru, Thanmai, et al.
Publicado: (2020) -
The Role of Type 2 Diabetes in Pancreatic Cancer
por: George, Sheeba, et al.
Publicado: (2022) -
Pancreatitis Prevention in Tabuk City, Kingdom of Saudi Arabia: Evaluating Public Knowledge and Raising Awareness of Risk Factors and Symptoms
por: Alalawi, Yousef, et al.
Publicado: (2023) -
In Vitro Human Fetal Pancreatic Islets to Redefine Pancreatic Research
por: Rout, Sipra, et al.
Publicado: (2023)